

**IN THE UNITED STATES DISTRICT COURT  
FOR THE WESTERN DISTRICT OF NORTH CAROLINA  
CHARLOTTE DIVISION  
CASE NO. 3:21-CV-129-MOC-DCK**

**ZAKLADY FARMACEUTYCZNE  
POLPHARMA S.A.,**

**Plaintiff,**

**vs.**

**KARTHA PHARMACEUTICALS, INC.,**

**Defendant.**

**RUBICON RESEARCH PRIVATE  
LIMITED,**

**Plaintiff,**

**vs.**

**KARTHA PHARMACEUTICALS INC.,  
and MANOJ BABU MAZHUVANCHERIL,**

**Defendants.**

**ORDER**

**THIS MATTER IS BEFORE THE COURT** on the “Joint Motion To Amend Protective Order” (Document No. 95) filed November 5, 2021. This motion has been referred to the undersigned Magistrate Judge pursuant to 28 U.S.C. § 636(b), and immediate review is appropriate. Having carefully considered the motion and the record, the undersigned will grant the motion. The terms of the Consent Order are hereby entered as follows:

**WHEREAS** the Court has ordered Polpharma and Kartha to resolve the merits of their dispute in the pending Swiss arbitration (SR Case No. 600639-2021) (Document No. 79);

**WHEREAS** permitting Swiss arbitration counsel to access and use discovery that has been exchanged by Polpharma and Kartha in the U.S. litigation will reduce costs for all parties involved;

**WHEREAS** Polpharma and Kartha have agreed to permit Swiss arbitration counsel to access and use documents that they have designated as Confidential or Attorney Eyes Only under the Protective Order in this case (Document No. 20), provided that Swiss arbitration counsel shall treat such documents as subject to Article 44 of the Swiss Rules of International Arbitration; and


**WHEREAS** Rubicon does not oppose such a modification to the Protective Order;

It is hereby **ORDERED** by the Court that:

1. Polpharma and Kartha may provide their respective Swiss arbitration counsel with access to any discovery provided by Polpharma or by Kartha in this case, including contemporaneous documents, deposition transcripts, and expert reports, for use only in the related Swiss arbitration (SR Case No. 600639-2021).
2. In providing such access, Polpharma and Kartha shall instruct their Swiss arbitration counsel that all discovery that has been marked Confidential or Attorney Eyes Only shall remain confidential and is subject to Article 44 of the Swiss Rules of International Arbitration.

**SO ORDERED.**

Signed: November 5, 2021

  
\_\_\_\_\_  
David C. Keesler  
United States Magistrate Judge



*/s/ Sara R. Lincoln*

---

Sara R. Lincoln, NC State Bar #22744  
Heather C. Fuller, NC State Bar #52497  
**LINCOLN DERR PLLC**  
4350 Congress Street, Suite 575  
Charlotte, NC 28209  
Tel: (704) 496-4500  
Fax: (866) 393-6043  
sara.lincoln@lincolnderr.com  
heather.fuller@lincolnderr.com

*Attorneys for Defendants*

*/s/ Stacie C. Knight*

---

Stacie C. Knight, N.C. Bar No. 28482  
**WINSTON & STRAWN LLP**  
300 South Tryon Street, 16th Floor  
Charlotte, NC 28202  
Tel: (704) 350-7712  
Fax: (704) 350-7800  
sknight@winston.com

Charles B. Klein\*  
Spencer W. Churchill\*  
D. Chanslor Gallenstein\*  
1901 L St. NW  
Washington DC 20036  
(202) 282-5000  
(202) 282-5100  
cklein@winston.com  
schurchill@winston.com  
cgallenstein@winston.com

*\* Pro hac vice*

*Attorneys for Plaintiff Zakłady  
Farmaceutyczne Polpharma S.A.*

Dated: November 5, 2021